Prof. Dr. Heinz Ludwig
Cavo M, Rajkumar SV, Palumbo A, Moreau P, Orlowski R, Bladé J, Sezer O, Ludwig H, Dimopoulos MA, Attal M, Sonneveld P, Boccadoro M, Anderson KC, Richardson PG, Bensinger W, Johnsen H, Kroeger N, Gahrton G, Bergsagel PL, Vesole DH, Einsele H, Jagannath S, Niesvizky R, Durie BG, Lonial S. International Myeloma Working Group (IMWG) consensus approach to the treatment of multiple myeloma patients who are candidates for autologous stem-cell transplantation. Blood. 2011 Mar 29. [Epub ahead of print]
Ludwig H, Beksac M, Bladé J, Cavenagh J, Cavo M, Delforge M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Kropff M, Leal da Costa F, Louw V, Magen-Nativ H, Mendeleeva L, Nahi H, Plesner T, San-Miguel J, Sonneveld P, Udvardy M, Sondergeld P, Palumbo A. Multiple Myeloma Treatment Strategies with Novel Agents in 2011: A European Perspective. Oncologist. 2011 Mar 26. [Epub ahead of print]
Gascón P, Aapro M, Ludwig H, Rosencher N, Boccadoro M, Turner M, Macdonald K, Muenzberg M, Abraham I. Update on the MONITOR-GCSF study of biosimilar filgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia in cancer patients: Protocol amendments. Crit Rev Oncol Hematol. 2011 Mar;77(3):198-200.
Dimopoulos MA, Palumbo A, Attal M, Beksaç M, Davies FE, Delforge M, Einsele H, Hajek R, Harousseau JL, da Costa FL, Ludwig H, Mellqvist UH, Morgan GJ, San-Miguel JF, Zweegman S, Sonneveld P. Optimizing the use of lenalidomide in relapsed or refractory multiple myeloma: consensus statement. Leukemia. 2011 Feb 4. [Epub ahead of print]
Dimopoulos M, Kyle R, Fermand JP, Rajkumar SV, San Miguel J, Chanan-Khan A, Ludwig H, Joshua D, Mehta J, Gertz M, Avet-Loiseau H, Beksaç M, Anderson KC, Moreau P, Singhal S, Goldschmidt H, Boccadoro M, Kumar S, Giralt S, Munshi NC, Jagannath S. Guidelines for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood. 2011 Feb 3. [Epub ahead of print]
Rajkumar SV, Harousseau JL, Durie B, Anderson KC, Dimopoulos M, Kyle R, Blade J, Richardson P, Orlowski R, Siegel D, Jagannath S, Facon T, Avet-Loiseau H, Lonial S, Palumbo A, Zonder J, Ludwig H, Vesole D, Sezer O, Munshi NC, San Miguel J. Consensus recommendations for the uniform reporting of clinical trials: report of the International Myeloma Workshop Consensus Panel 1. Blood. 2011 Feb 3. [Epub ahead of print]
Müldür E, Chott A, Mirzaei S, Zojer N, Ludwig H. Patient with high-grade Fever, night sweats, and hepatosplenomegaly. J Clin Oncol. 2011 Apr 1;29(10):e254-6.
Ludwig H. BMP-2: a culprit for anemia in myeloma. Blood. 2010 Nov 4;116(18):3383-4.
Dimopoulos MA, Terpos E, Chanan-Khan A, Leung N, Ludwig H, Jagannath S, Niesvizky R, Giralt S, Fermand JP, Bladé J, Comenzo RL, Sezer O, Palumbo A, Harousseau JL, Richardson PG, Barlogie B, Anderson KC, Sonneveld P, Tosi P, Cavo M, Rajkumar SV, Durie BG, San Miguel J. Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the international myeloma working group. J Clin Oncol. 2010 Nov 20;28(33):4976-84. Epub 2010 Oct 18.
Delforge M, Bladé J, Dimopoulos MA, Facon T, Kropff M, Ludwig H, Palumbo A, Van Damme P, San-Miguel JF, Sonneveld P. Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues. Lancet Oncol. 2010 Nov;11(11):1086-95.
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A. Treatment of relapsed and refractory multiple myeloma in the era of novel agents. Cancer Treat Rev. 2010 Sep 20. [Epub ahead of print]
Ludwig H, Adam Z, Hajek R, Greil R, Tóthová E, Keil F, Autzinger EM, Thaler J, Gisslinger H, Lang A, Egyed M, Womastek I, Zojer N. Light chain-induced acute renal failure can be reversed by bortezomib-doxorubicin-dexamethasone in multiple myeloma: results of a phase II study. J Clin Oncol. 2010 Oct 20;28(30):4635-41. Epub 2010 Sep 7.
Lamm W, Willenbacher W, Lang A, Zojer N, Müldür E, Ludwig H, Schauer-Stalzer B, Zielinski CC, Drach J. Efficacy of the combination of bortezomib and dexamethasone in systemic AL amyloidosis. Ann Hematol. 2010 Sep 7. [Epub ahead of print]
Terpos E, Dimopoulos MA, Sezer O, Roodman D, Abildgaard N, Vescio R, Tosi P, Garcia-Sanz R, Davies F, Chanan-Khan A, Palumbo A, Sonneveld P, Drake MT, Harousseau JL, Anderson KC, Durie BG; International Myeloma Working Group. The use of biochemical markers of bone remodeling in multiple myeloma: a report of the International Myeloma Working Group. Leukemia. 2010 Oct;24(10):1700-12. Epub 2010 Sep 2. Review.
Engelhardt M, Udi J, Kleber M, Spencer A, Rocci A, Knop S, Bruno B, Bringhen S, Pérez-Simón JA, Zweegman S, Driessen C, Patriarca F, Gramatzki M, Terpos E, Sezer O, Kropff M, Straka C, Johnsen HE, Waage A, Boegsted M, Lokhorst H, Hájek R, Morgan G, Boccadoro M, Ludwig H, Cavo M, Polliack A, Sonneveld P, Einsele H, Palumbo A. European Myeloma Network: the 3rd Trialist Forum Consensus Statement from the European experts meeting on multiple myeloma. Leuk Lymphoma. 2010 Nov;51(11):2006-11. Epub 2010 Aug 31.
Moehler TM, Feneberg R, Ho AD, Golenkov AK, Ludwig H, Kropff M, Khuageva NK, Hajda J, von Broen I, Goldschmidt H. Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma. Anticancer Drugs. 2010 Aug;21(7):708-15.
Burger S, Lehnert M, Ludwig H. [Erythropoiesis stimulating proteins for the treatment of anemia in cancer patients] Ther Umsch. 2010 May;67(5):271-6. Review. German.
Zojer N, Ludwig H. Chronic lymphocytic leukaemia – emerging treatment options: a report from the ASH Meeting 2009. Memo 2010 (3): 65-68
Ludwig H, Adam Z, Tothova E, Hajek R, Labar B, Egyed M, Spicka I, Gisslinger H, Drach J, Kuhn I, Hinke A, Zojer N. Thalidomide maintenance treatment increases progression-free but not overall survival in elderly patients with myeloma. Haematologica. 2010 Apr 23.
Kyle RA, Durie BG, Rajkumar SV, Landgren O, Blade J, Merlini G, Kröger N, Einsele H, Vesole DH, Dimopoulos M, San Miguel J, Avet-Loiseau H, Hajek R, Chen WM, Anderson KC, Ludwig H, Sonneveld P, Pavlovsky S, Palumbo A, Richardson PG, Barlogie B, Greipp P, Vescio R, Turesson I, Westin J, Boccadoro M. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia. 2010 Apr 22.
Ludwig H, Zojer N. Renal recovery with lenalidomide in a patient with bortezomib-resistant multiple myeloma. Nat Rev Clin Oncol. 2010 May;7(5):289-94.
Gascón P, Aapro M, Ludwig H, Rosencher N, Turner M, Song M, Macdonald K, Lee C, Muenzberg M, Abraham I. Background and methodology of MONITOR-GCSF, a pharmaco-epidemiological study of the multi-level determinants, predictors, and clinical outcomes of febrile neutropenia prophylaxis with biosimilar granulocyte-colony stimulating factor filgrastim. Crit Rev Oncol Hematol. 2010 Feb 26
Ludwig H, Bolejack V, Crowley J, Bladé J, San Miguel J, Kyle RA, Rajkumar SV, Shimizu K, Turesson I, Westin J, Sonneveld P, Cavo M, Boccadoro M, Palumbo A, Tosi P, Harousseau JL, Attal M, Barlogie B, Stewart AK, Durie B. Survival and Years of Life Lost in Different Age Cohorts of Patients With Multiple Myeloma. J Clin Oncol. 2010 Feb 22.
Ludwig H, Beksac M, Bladé J, Boccadoro M, Cavenagh J, Cavo M, Dimopoulos M, Drach J, Einsele H, Facon T, Goldschmidt H, Harousseau JL, Hess U, Ketterer N, Kropff M, Mendeleeva L, Morgan G, Palumbo A, Plesner T, San Miguel J, Shpilberg O, Sondergeld P, Sonneveld P, Zweegman S. Current multiple myeloma treatment strategies with novel agents: a European perspective. Oncologist. 2010;15(1):6-25. Epub 2010 Jan 19.
Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010 Jan 19;102(2):301-15. Epub 2010 Jan 5.
Spivak JL, Gascón P, Ludwig H. Anemia management in oncology and hematology. Oncologist. 2009;14 Suppl 1:43-56. Review.
Ludwig H. Autologous stem cell transplantation in multiple myeloma – contra. Dtsch Med Wochenschr. 2009 Sep;134(39):1943. Epub 2009 Sep 16.
Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, Vermorken J, Hamilton L, Bridges K, Pujol B. Darbepoetin alfa for treating chemotherapy-induced anemia in patients with a baseline hemoglobin level < 10 g/dL versus > or = 10 g/dL: an exploratory analysis from a randomized, double-blind, active-controlled trial. BMC Cancer. 2009 Sep 3;9:311.
Aapro M, Ludwig H, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, Albrecht T, Abraham I. Modeling of treatment response to erythropoiesis-stimulating agents as a function of center- and patient-related variables: results from the Anemia Cancer Treatment (ACT) study. Ann Oncol. 2009 Oct;20(10):1714-21
Kumar S, Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Lentzsch S, Munshi N, Niesvizky R, San Miguel J, Ludwig H, Bergsagel L, Blade J, Lonial S, Anderson KC, Tosi P, Sonneveld P, Sezer O, Vesole D, Cavo M, Einsele H, Richardson PG, Durie BG, Rajkumar SV; International Myeloma Working Group. Mobilization in myeloma revisited: IMWG consensus perspectives on stem cell collection following initial therapy with thalidomide-, lenalidomide-, or bortezomib-containing regimens. Blood. 2009;114(9):1729-35.
Giralt S, Stadtmauer EA, Harousseau JL, Palumbo A, Bensinger W, Comenzo RL, Kumar S, Munshi NC, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos MA, Einsele H, Barlogie B, Anderson KC, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson PG, Niesvizky R, Rajkumar SV, Durie BG. International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100). Leukemia. 2009 Jun 25.
Palumbo A, Sezer O, Kyle R, Miguel JS, Orlowski RZ, Moreau P, Niesvizky R, Morgan G, Comenzo R, Sonneveld P, Kumar S, Hajek R, Giralt S, Bringhen S, Anderson KC, Richardson PG, Cavo M, Davies F, Bladé J, Einsele H, Dimopoulos MA, Spencer A, Dispenzieri A, Reiman T, Shimizu K, Lee JH, Attal M, Boccadoro M, Mateos M, Chen W, Ludwig H, Joshua D, Chim J, Hungria V, Turesson I, Durie BG, Lonial S. International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation. Leukemia. 2009 Oct;23(10):1716-30
Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG; International Myeloma Working Group. International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009 Feb;23(2):215-24. Epub 2008 Nov 20.
Terpos E, Cibeira MT, Blade J, Ludwig H. Management of complications in multiple myeloma. Semin Hematol. 2009;46(2):176-89
Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA. Pooled Analysis of Individual Patient-Level Data From All Randomized, Double-Blind, Placebo-Controlled Trials of Darbepoetin Alfa in the Treatment of Patients With Chemotherapy-Induced Anemia. JCO 2009
Fink AM, Filz D, Krajnik G, Jurecka W , Ludwig H, Steiner A. Seborrhoeic keratoses in patients with internal malignancies: a case–control study with prospective accrual of patients. J Eur Acad Dermatol Venereol. 2009 Mar 4.
Ludwig H, Aapro M, Bokemeyer C, Macdonald K, Soubeyran P, Turner M, Albrecht T, Abraham I. Treatment patterns and outcomes in the management of anaemia in cancer patients in Europe: Findings from the Anaemia Cancer Treatment (ACT) study. Eur J Cancer. 2009
Lehnert M, Ludwig H, Zojer N. Update on the rational use of Y-ibritumomab tiuxetan in the treatment of follicular lymphoma. Onco Targets Ther. 2009 Feb 18;2:199-208.
Strasser-Weippl K, Ludwig H. A reply to Efficaces’ letter to the editor. Eur J Haematol. 2009
Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P. Fluorouracil, Leucovorin, and Oxaliplatin With and Without Cetuximab in the First-Line Treatment of Metastatic Colorectal Cancer. JCO 2009;27(5):663-71.
Baselga J, Zambetti M, Llombart-Cussac A, Manikhas G, Kubista E, Steger G, Makhson A, Tjulandin S, Ludwig H, Verrill M, Ciruelos E, Egyhazi S, Xu L, Zerba K, Lee H, Clark E, Galbraith S. Phase II Genomics Study of Ixabepilone as Neoadjuvant Treatment for Breast Cancer. JCO 2008
Ludwig H, Auberger T, Burghuber O Ch, Gnant M, Hopfinger G, Jäger U, Keil F, Kornek G, Linkesch W, Petru E, Pirker R, Pittermann E, Reinthaller A, Samonigg H, Steger G, Stockenhuber F, Studnicka M, Weiss G, Zielinski C. Wien Klin Wochenschr. 2008;120 (15-16):507-13.
Ludwig H, Anderson K, Dammacco F, Hedenus M, Osterborg A, Durie B. ESAs not the culprit: More studies required. Am J Hematol. 2008 Aug 19
Palumbo A, Dimopoulos M, Miguel JS, Harousseau JL, Attal M, Hussein M, Knop S, Ludwig H, von Lilienfeld-Toal M, Sonneveld P. Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood Rev 2008 Sep 5.
Strasser-Weippl K, Ludwig H. Psychosocial QOL is an independent predictor of overall survival in newly diagnosed patients with multiple myeloma. Eur J Haematol. 2008 Jul 11.
Ludwig H, Zojer N. Recent therapeutic advances in hematological malignancies: dealing with treatment-related complications. Ann Oncol. 2008 Jul;19 Suppl 5:v71-8.
Zojer N, Mirzaei S, Ludwig H. Successful treatment of a patient with lymphocyte-predominant Hodgkin’s lymphoma with yttrium-90-ibritumomab tiuxetan. Eur J Haematol. 2008 Jun 25.
Dimopoulos MA, Kastritis E, Rosinol L, Bladé J, Ludwig H. Pathogenesis and treatment of renal failure in multiple myeloma. Leukemia. 2008 Aug;22(8):1485-93. Epub 2008 Jun 5. Review.
Aapro MS, Birgegård G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Hellström-Lindberg E, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P. Erythropoietins should be used according to guidelines. Lancet Oncol. 2008 May;9(5):412-3.
Mellstedt H, Niederwieser D, Ludwig H. The challenge of biosimilars. Ann Oncol. 2008; 19: 411-419.
Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients under age 50 presents with more favorable features and shows better survival: an analysis of 10,549 patients from the International Myeloma Working Group. Blood. 2008 Feb 11;
Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M, Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL. Thalidomide for treatment of multiple myeloma: 10 years later. Blood. 2008 Feb 1.
Smith RE Jr, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008 Mar 1;26(7):1040-50.
Kaufmann H, Ackermann J, Odelga V, Sagaster V, Nösslinger T, Pfeilstöcker M, Keck A, Ludwig H, Gisslinger H, Drach J. Cytogenetic patterns in multiple myeloma after a phase of preceding MGUS. Eur J Clin Invest. 2008 Jan;38(1):53-60.
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson PG, San Miguel J, Barlogie B, Harousseau J, Zonder JA, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG, Sonneveld P, Hussein MA; International Myeloma Working Group. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008 Feb;22(2):414-23.
Ludwig H, Zojer N. Supportive care in multiple myeloma. Best Practice & Research Clinical Haematology Vol. 20, No. 4, pp. 817–835, 2007
Ludwig H, Strasser-Weippl K, Schreder M, Zojer N. Advances in the treatment of hematological malignancies: current treatment approaches in multiple myeloma. Ann Oncol. 2007 Jul;18 Suppl 9:ix64-70
Aapro M, Abraham I, Bokemeyer C, Ludwig H, Macdonald K, Soubeyran P, Turner M. The background and methodology of the Anaemia Cancer Treatment (A.C.T.) study: a global retrospective study of practice patterns and outcomes in the management of anaemia in cancer patients and their congruence with evidence-based guidelines. Support Care Cancer. 2007 Sep 14;
Ludwig H, Drach J, Graf H, Lang A, Meran JG. Reversal of acute renal failure by bortezomib-based chemotherapy in patients with multiple myeloma. Haematologica. 2007 Oct;92(10):1411-4
Heintel D, Zojer N, Schreder M, Strasser-Weippl K, Kainz B, Vesely M, Gisslinger H, Drach J, Gaiger A, Jager U, Ludwig H. Expression of MUM1/IRF4 mRNA as a prognostic marker in patients with multiple myeloma. Leukemia. 2007 Aug 9, 1-4.
Ludwig H, Zojer N, Drach J. The impact of novel agents in patients with poor prognosis myeloma defined by unfavorable cytogenetics, high age, and renal failure. Proceedings of the XI International Myeloma Workshop, Kos, June 2007.
Strasser-Weippl K, Ludwig H. A Survey among Oncologists on Measures Needed to Improve Cancer Care. Onkologie. 2007 Jul;30(7):367-72. Epub 2007 Jun 27.
Ludwig H. Is bortezomib active in patients with mantle cell lymphoma? Nat Clin Pract Oncol. 2007 May;4(5):276-7.
Sagaster V, Kaufmann H, Odelga V, Ackermann J, Gisslinger H, Rabitsch W, Zojer N, Ludwig H, Nosslinger T, Zielinski C, Drach J. Chromosomal abnormalities of young multiple myeloma patients. Eur J Haematol. 2007 Mar;78(3):227-34.
Ludwig H, Zojer N. Supportive care. Ann Oncol. 2007 Feb;18 Suppl 1:i37-i44.
Zojer N, Ludwig H. Hematological emergencies. Ann Oncol. 2007 Feb;18 Suppl 1:i45-i48.
Pohl G, Seemann H, Zojer N, Ochsner C, Luhan C, Schemper M, Ludwig H. “Laying on of hands” improves well-being in patients with advanced cancer. Support Care Cancer. 2007 Feb;15(2):143-51.
Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Kuenburg E, Wieser R, Zielinski C, Drach J. Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion. Leukemia. 2007 Jan;21(1):164-8.
Dicato M, Boccadoro M, Cavenagh J, Harousseau JL, Ludwig H, San Miguel J, Sonneveld P. Management of multiple myeloma with bortezomib: experts review the data and debate the issues. Oncology. 2006;70(6):474-82.
Strasser-Weippl K, Steurer M, Kees M, Augustin F, Tzankov A, Dirnhofer S, Fiegl M, Simonitsch-Klupp I, Gisslinger H, Zojer N, Ludwig H. Prognostic relevance of cytogenetics determined by fluorescent in situ hybridization in patients having myelofibrosis with myeloid metaplasia. Cancer. 2006 Dec 15;107(12):2801-6.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G. International uniform response criteria for multiple myeloma. Leukemia. 2006 Dec;20(12):2220
Birgegard G, Gascon P, Ludwig H. Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY. Eur J Haematol. 2006 Nov;77(5):378-86.
Vincent M, Dranitsaris G, Verma S, Lau C, Gascon P, Van Belle S, Ludwig H. The development and validation of a prediction tool for chemotherapy-induced anemia in patients with advanced nonsmall cell lung cancer receiving palliative chemotherapy. Support Care Cancer. 2006 Nov 21
Ludwig H. Iron metabolism and iron supplementation in anemia of cancer. Semin Hematol. 2006 Oct;43(4 Suppl 6):S13-7.
Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, Gertz M, Dimopoulos M, Westin J, Sonneveld P, Ludwig H, Gahrton G, Beksac M, Crowley J, Belch A, Boccadaro M, Turesson I, Joshua D, Vesole D, Kyle R, Alexanian R, Tricot G, Attal M, Merlini G, Powles R, Richardson P, Shimizu K, Tosi P, Morgan G, Rajkumar SV; International Myeloma Working Group. International uniform response criteria for multiple myeloma. Leukemia. 2006 Sep;20(9):1467-73.
Ludwig H and members of the task force. ASCO-ESMO consensus statement on quality cancer care. Ann Oncol. 2006 Jul;17(7):1063-4 und J Clin Oncol. 2006 Jul 20;24(21):3498-9.
Ludwig H. Keynote comment: inequalities and shortcomings in European cancer care. Lancet Oncol. 2006 Apr;7(4):276-7.
Ludwig H. Epoetin beta in oncology: examining the current evidence. Fut Oncol. 2006 Feb;2(1):21-38.
Barrett-Lee PJ, Ludwig H, Birgegard G, Bokemeyer C, Gascon P, Kosmidis PA, Krzakowski M, Nortier JW, Kongable G, Schneider M, Schrijvers D, Van Belle SJ; European Cancer Anaemia Survey Advisory Board and Participating Centers. Independent risk factors for anemia in cancer patients receiving chemotherapy: results from the European Cancer Anaemia Survey. Oncology. 2006;70(1):34-48.
San Miguel J, Blade J, Boccadoro M, Cavenagh J, Glasmacher A, Jagannath S, Lonial S, Orlowski RZ, Sonneveld P, Ludwig H. A practical update on the use of bortezomib in the management of multiple myeloma. Oncologist. 2006 Jan;11(1):51-61.
Gascon P, Ludwig H. Response to the publication: EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer. Eur J Cancer. 2005 Dec;41(18):2789-91.
Ludwig H, Spicka I, Klener P, Greil R, Adam Z, Gisslinger H, Tarkovacs G, Linkesch W, Maniatis A, Morant R, Drach J, Kuhn I, Schuster J, Hinke A. Continuous prednisolone versus conventional prednisolone with VMCP-interferon-alpha2b as first-line chemotherapy in elderly patients with multiple myeloma. Br J Haematol. 2005 Nov;131(3):329-37.
Ludwig H, Khayat D, Giaccone G, Facon T. Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies. Cancer. 2005 Nov 1;104(9):1794-807.
Ludwig H, Pohl G, Osterborg A. Anemia in multiple myeloma. Clin Adv Hematol Oncol. 2004 Apr;2(4):233-41.
Kosmidis PA, Ludwig H, Mellstedt H. ESMO at 30: mission ongoing. Ann Oncol. 2005 Sep;16(9):1411-2.
Ludwig H. Advances in biology and treatment of multiple myeloma. Ann Oncol. 2005;16 Suppl 2:ii106-12. Review.
Blohmer JU, Dunst J, Harrison L, Johnston P, Khayat D, Ludwig H, O’Brien M, Van Belle S, Vaupel P.Cancer-related anemia: biological findings, clinical implications and impact on quality of life. Oncology. 2005;68 Suppl 1:12-21. Review.
Birgegard G, Aapro MS, Bokemeyer C, Dicato M, Drings P, Hornedo J, Krzakowski M, Ludwig H, Pecorelli S, Schmoll H, Schneider M, Schrijvers D, Shasha D, Van Belle S.Cancer-related anemia: pathogenesis, prevalence and treatment. Oncology. 2005;68 Suppl 1:3-11. Review.
Amadori S, Fenaux P, Ludwig H, O’dwyer M, Sanz M. Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin. 2005 Mar;21(3):403-11. Review.
Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol. 2005 May 20;23(15):3412-20.
Ludwig H. A foundation for the future. Ann Oncol. 2005 Jan;16(1):3.
Ludwig H, Hudis CA, Goss G, Leyland-Jones B. Epoetin alfa: future directions and future research. Oncologist. 2004;9 Suppl 5:70-3.
Ludwig H. rHuEPO and treatment outcomes: the preclinical experience. Oncologist. 2004;9 Suppl 5:48-54.
Ludwig H, Van Belle S, Barrett-Lee P, Birgegard G, Bokemeyer C, Gascon P, Kosmidis P, Krzakowski M, Nortier J, Olmi P, Schneider M, Schrijvers D. The European Cancer Anaemia Survey (ECAS): a large, multinational, prospective survey defining the prevalence, incidence, and treatment of anaemia in cancer patients. Eur J Cancer. 2004 Oct;40(15):2293-306.
Ludwig H. Optimum cancer care–an unaffordable goal? Lancet Oncol. 2004 Sep;5(9):529-30.
Ludwig H. Multiple Myeloma Research Foundation. Supportive therapies in the management of myeloma. Oncology (Williston Park). 2004 Mar;18(3):295-6, 298.